HC Wainwright Has Optimistic Outlook of Evommune Q2 Earnings

Evommune, Inc. (NYSE:EVMN) – Analysts at HC Wainwright boosted their Q2 2026 EPS estimates for shares of Evommune in a research report issued on Tuesday, May 26th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings of ($0.68) per share for the quarter, up from their prior forecast of ($0.71). HC Wainwright currently has a “Buy” rating and a $50.00 target price on the stock. The consensus estimate for Evommune’s current full-year earnings is ($2.86) per share. HC Wainwright also issued estimates for Evommune’s Q3 2026 earnings at ($0.70) EPS, Q4 2026 earnings at ($0.74) EPS, FY2026 earnings at ($2.77) EPS, Q1 2027 earnings at ($0.77) EPS, Q2 2027 earnings at ($0.82) EPS, Q3 2027 earnings at ($0.86) EPS, Q4 2027 earnings at ($0.90) EPS and FY2027 earnings at ($3.33) EPS.

EVMN has been the topic of a number of other reports. Stifel Nicolaus assumed coverage on shares of Evommune in a report on Friday, May 1st. They issued a “buy” rating and a $54.00 target price on the stock. Evercore reaffirmed an “outperform” rating and issued a $55.00 target price on shares of Evommune in a report on Tuesday, February 10th. Weiss Ratings assumed coverage on shares of Evommune in a report on Tuesday, February 3rd. They issued a “sell (e)” rating on the stock. Clear Str raised shares of Evommune to a “strong-buy” rating in a report on Tuesday, March 17th. Finally, Oppenheimer started coverage on shares of Evommune in a research report on Tuesday, April 7th. They issued an “outperform” rating and a $50.00 price objective on the stock. Three investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $49.25.

Evommune Stock Up 0.2%

Shares of Evommune stock opened at $23.39 on Thursday. The firm has a fifty day simple moving average of $24.20. The firm has a market cap of $842.62 million and a PE ratio of -2.46. Evommune has a 12 month low of $13.89 and a 12 month high of $33.20.

Evommune (NYSE:EVMN) last announced its earnings results on Thursday, May 7th. The company reported ($0.64) EPS for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.19.

Hedge Funds Weigh In On Evommune

Hedge funds and other institutional investors have recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. purchased a new position in Evommune in the 4th quarter valued at $34,000. Strs Ohio purchased a new position in Evommune in the 1st quarter valued at $41,000. The Manufacturers Life Insurance Company purchased a new position in Evommune in the 4th quarter valued at $179,000. XTX Topco Ltd purchased a new position in Evommune in the 4th quarter valued at $321,000. Finally, Oxford Asset Management LLP purchased a new position in Evommune in the 4th quarter valued at $335,000.

About Evommune

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.